Eli Lilly and Company
PulseAugur coverage of Eli Lilly and Company — every cluster mentioning Eli Lilly and Company across labs, papers, and developer communities, ranked by signal.
- invested by Insilico Medicine 95%
- acquired by Insilico Medicine 95%
- invested in Insilico Medicine 95%
- acquired Insilico Medicine 95%
- developed tirzepatide 90%
- competes with Novo Nordisk 90%
- competes with Wegovy 80%
- other Novo Nordisk 70%
- competes with tirzepatide 70%
- invested in tirzepatide 60%
- instance of tirzepatide 60%
- partners with Insilico Medicine 50%
- 2026-08-05 product_launch Eli Lilly and Company reported significant revenue growth driven by its GLP-1 drugs and highlighted promising trial results for its next-generation weight-loss drug, retatrutide. source
- 2026-06-08 product_launch Eli Lilly launched LillyDirect, a direct-to-consumer platform for its weight-loss medications. source
- 2026-05-26 funding Eli Lilly is planning to acquire three vaccine development companies for nearly $4 billion. source
2 day(s) with sentiment data
-
New two-step method simplifies antibody-drug conjugate creation for cancer therapies
Researchers have developed a novel two-step process for creating more uniform antibody-drug conjugates (ADCs). This method precisely attaches cancer drugs to a specific site on antibodies, streamlining the development o…
-
Eli Lilly invests $2.75B in AI-designed drugs from Insilico Medicine
Eli Lilly and Company has acquired drug candidates designed by Insilico Medicine for $2.75 billion. This significant investment highlights the growing role of artificial intelligence in pharmaceutical drug discovery. Th…
-
AI giants pivot to health care to boost image and investor confidence · 1 source tracked
Major AI companies are increasingly focusing on health care applications to improve their public image and secure investor confidence. This strategic shift aims to counter negative perceptions surrounding AI's environme…
-
US prescription drug prices fall 3.1% amid IRA negotiations and market shifts
Prescription drug prices in the U.S. have seen a significant decline, with a 3.1% drop over the past year, marking the steepest annual decrease in over six decades. This trend is attributed to a combination of factors, …
-
Tribeca Festival Showcases Vital Stories on Disease and Patient Experiences
Three short films, "Reconstructing Charlie," "Run It Back," and "Do I Know You From Somewhere?" premiered as part of the Vital Stories program at the 2026 Tribeca Film Festival. This initiative, supported by Eli Lilly a…
-
Tech Giants Face Lawsuits Over Social Media Addiction; GLP-1 Drugs Show Brain Health Promise
A recent court ruling allows thousands of lawsuits alleging social media addiction to proceed against tech giants like Meta. Separately, researchers are exploring the potential of GLP-1 drugs, such as Ozempic, to treat …
-
Novo Nordisk faces growth challenges after Wegovy success, rival Eli Lilly gains ground
Novo Nordisk, once Europe's most valuable company due to the success of its weight-loss drugs Ozempic and Wegovy, is facing challenges in developing new blockbuster treatments. Its rival, Eli Lilly and Company, has gain…
-
Eli Lilly's Obesity Drugs Fuel 48% Revenue Growth, Retatrutide Trials Show Promise
Eli Lilly and Company reported a significant increase in its second-quarter revenue, reaching $23 billion, a 48% year-over-year growth. This surge was primarily driven by its GLP-1 drugs, Mounjaro and Zepbound, which ge…
-
Apnimed raises $192M in IPO for sleep apnea pill
Apnimed, a biotech startup developing a pill for sleep apnea, has successfully raised $192 million in an upsized Initial Public Offering (IPO). The company's shares are set to trade on the Nasdaq, with the IPO valuing A…
-
AI accelerates drug discovery, but data quality and lab bottlenecks remain challenges · 4 sources tracked
Artificial intelligence is accelerating drug discovery by enabling predictive design of drug candidates, which reduces the need for extensive physical screening. However, this speed highlights bottlenecks in laboratory …
-
Model Gateway platform streamlines AI-driven drug discovery
A new platform called Model Gateway has been developed to manage machine learning and scientific computational models specifically for drug discovery. This cloud-based system offers features like version control, govern…
-
Eli Lilly invests $2.75B in AI drug discovery firm Insilico Medicine
Eli Lilly and Company has acquired Insilico Medicine for $2.75 billion, highlighting a significant trend of major pharmaceutical companies investing heavily in AI-driven drug discovery. This single-week investment surge…
-
Geely Deep Blue plans share buyback amid other industry news
Geely Deep Blue announced a plan to repurchase shares worth 50 million to 100 million yuan, with the repurchase price not exceeding 25 yuan per share. This move aims to maintain the company's value and protect sharehold…
-
Novo Nordisk sues Eli Lilly over drug ad claims; China insurance experts discuss AI
Novo Nordisk has filed a lawsuit against Eli Lilly and Company in a U.S. federal court. The lawsuit alleges that Eli Lilly's advertisements for its weight-loss drug Zepbound and diabetes drug Mounjaro are misleading. Se…
-
Eli Lilly acquires AtaiBeckley for $3.8B, signaling Big Pharma's major bet on psychedelic medicine
Eli Lilly has announced a significant acquisition of AtaiBeckley for up to $3.8 billion, marking the largest deal in the psychedelic medicine sector. This move, along with AbbVie's prior acquisition, signals a major shi…
-
Institutions trade tech stocks; Eli Lilly acquires Atai Beckley; DeepSeek eyes IPO
On July 16th, institutional investors showed activity across 54 stocks, with net buying in 20 and net selling in 34. Huatian Technology, Maige Mite, and Haesken Huijgensdr were among the top net buys, while Montage Tech…
-
Eli Lilly to acquire AtaiBeckley for $2.8B; Uber buys Delivery Hero
Eli Lilly has agreed to acquire AtaiBeckley for approximately $2.8 billion in cash, with potential for an additional $1 billion in milestone payments. This acquisition aims to bolster Eli Lilly's pipeline for treating r…
-
Autoimmune disease therapies boom amid VC investment; OpenAI targets healthcare
The field of autoimmune disease therapies is experiencing a significant boom, with projected revenues for drugs like AbbVie's Skyrizi expected to reach $33 billion by 2032. This growth is driven by scientific breakthrou…
-
Takeda partners with Insilico Medicine for $600M AI drug discovery deal
Takeda Pharmaceutical Company has entered into a strategic collaboration with Insilico Medicine, utilizing AI for early-stage drug discovery. The deal, potentially worth up to US$600 million, grants Takeda exclusive wor…
-
Axsome Therapeutics stock doubles on Alzheimer's drug approval
Axsome Therapeutics has seen its stock price double in the past nine months, reaching a market capitalization of $12.6 billion. This significant growth is largely attributed to the recent FDA approval of its drug Auveli…